Biosupply Trends Marketplace News
Monday, February 15, 2021
Banner Image - Patient Safety, Product Integrity, Fair Pricing
biosupply button green pixel top of biosupply button Spacer image top of Verified Inventory Program button
Biosupply, place your product order Spacer image MyFluVaccine, place your vaccine order Spacer image Verified Inventory Program, sign up for streamlined inventory

Study Shows COVID-19 Triggers Antibodies from Previous Coronavirus Infections

Main article image

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly

Researchers at Northern Arizona University and the Translational Genomics Research Institute have found people with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease, which may partially explain the difference in symptom severity between old and young patients. read more ]

UC-MSC Infusions Reduce the Risk of Death and Time to Recovery for Severe COVID-19 Disease

Investigators at the University of Miami's Diabetes Research Institute and Cell Transplant Center, along with a team of international collaborators, have discovered umbilical cord-derived mesenchymal stem cell (UC-MSC) infusions safely reduce the risk of both death and the time to recovery for severe cases of the COVID-19 disease. After treatment, the survival rate at one month was 91 percent compared to 42 percent in the placebo group, more than half of patients treated recovered within two weeks and were discharged from the hospital, and more than 80 percent of the group recovered by day 30, compared to just 37 percent in the control group. read more ]

Study Shows Immunity to COVID-19 May Last Months After Infection

A study conducted at Monash University in Australia that examined the immune reactions in 36 blood samples from 25 COVID-19 patients starting on day four post-infection through day 242 post-infection has found their immune memory to the virus lasts at least eight months. While previous studies show patients likely only carry antibodies to coronavirus for a few months, the Australian team says their findings are the strongest evidence vaccines will provide long-lasting protection. read more ]

New Research Shows COVID-19 May Be Seasonal Like Influenza

In a study that analyzed COVID-19 data — including cases, death rates, recoveries, testing rates and hospitalizations — from 221 countries, investigators found a strong association with temperature and latitude that is not directly controlled by the genomic makeup of the virus. read more ]

Industry News

Industry News Image

From Eli Lilly and Company

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19. The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions.  [ read more ]

From Ridgeback Biotherapeutics

Ebanga has been approved by the U.S. Food and Drug Administration (FDA) to treat Ebola. It is currently approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, and is the only FDA-approved, single-injection Ebola treatment available in a lyophilized form. read more ]

From AstraZeneca and the University of Oxford

A study conducted in the United Kingdom shows the Oxford-AstraZeneca COVID-19 vaccine revealed single standard-dose efficacy of 76 percent from day 22 to day 90 post-vaccination with protection not falling in this three-month period, and after the second dose, vaccine efficacy is 82.4 percent. In addition, analyses of PCR positive swabs suggest the vaccine may have a substantial effect on transmission of the virus with 67 percent reduction in positive swabs among those vaccinated. read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand

What's New at FFF


FENTANYL CITRATE injection is indicated for 1) analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises; 2) use as an opioid analgesic supplement in general or regional anesthesia; 3) administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia; and 4) use as an anesthetic agent with oxygen in selected high-risk patients such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures. The USP equivalent to 50 mcg is supplied in clamcells of 10 2 mL and 5mL single-dose amuples; trays containing 25 2 mL, 5 mL, 10 mL, 20 mL and 50 mL single-dose fliptop vials; and cartons containing five 10 mL and 20 mL single-dose ampules.

For more information about FENTANYL CITRATE, log in to


DOCETAXEL injection is indicated for treatment of patients with 1) locally advanced or metastatic breast cancer after failure of prior chemotherapy, and in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive breast cancer; 2) locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, and in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition; 3) metastatic castration-resistant prostate cancer in combination with prednisone; 4) advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease; and 5) locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil. It is supplied in 20 mg/1 mL single-dose vials, and 80 mg/4 mL and 160 mg/8 mL multiple-dose vials as a sterile, pyrogen-free, non-aqueous pale-yellow to brownish yellow solution.

For more information about DOCETAXEL, log in to


DIAZEPAM injection is indicated for 1) relief of acute anxiety when rapid action is required; 2) acute alcohol withdrawal; 3) a useful adjunct in endoscopic procedures, skeletal muscle spasm associated with local pathology, cerebral palsy, athetosis, stiff-man syndrome and tetanus, as well as status epilepticus and severe recurrent convulsive seizures; and 4) premedication in patients undergoing surgical procedures and cardioversion. It is supplied in 10 mL multiple-dose vials containing 50 mg (5 mg/mL).

For more information about DIAZEPAM, log in to


LABETALOL HYDROCHLORIDE injection, UPS, is indicated for control of blood pressure in severe hypertension. It is supplied in a 4 mL (20 mg) Carpuject single-dose cartridge with a Luer Lock.

For more information about LABETALOL HYDROCHLORIDE, log in to


0.9% SODIUM CHLORIDE, injection, USP, is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection according to instructions of the manufacturer of the drug to be administered. It is supplied in tubs of 25 Carpuject single-dose cartridges with Luer Lock containing 3 mL or 5 mL; a tub of 50 Carpuject single-dose cartridges with Luer Lock containing 2 mL; in trays of 25 single-dose plastic fliptop vials containing 10 mL, 20 mL or 50 mL; and a tray of 25 single-dose LifeShield plastic fliptop vials containing 10 mL.

For more information about 0.9% SODIUM CHLORIDE, log in to


ZILRETTA (triamcinolone acetonide injectable suspension) is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. It is supplied as 1) a 5 mL single-dose vial to deliver 32 mg of triamcinolone acetonide supplied as a sterile white to off-white powder in a clear vial, and 2) a 5 mL single-dose vial supplied as a sterile, clear liquid solution of 0.9% w/w sodium chloride (normal saline) containing 0.5% w/w sodium carboxymethylcellulose, and 0.1% w/w polysorbate-80 in a glass vial.

For more information about ZILRETTA, call Wow! Customer Care at (800) 843-7477


XERAVA (ERAVACYCLINE) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. The yellow to orange sterile, preservative-free powder for reconstitution is supplied in single-dose 10 mL clear glass vials in 50 mg and 100 mg doses with a rubber stopper and an aluminum overseal.

For more information about XERAVA (ERAVACYCLINE), log in to


PROTONIX I.V. (pantoprazole sodium) for injection is indicated in adults for 1) short-term treatment (seven to 10 days) of gastroesophogeal reflex disease associated with a history of erosive esophagitis, and 2) pathological hypersecretion conditions, including Zollinger-Ellison syndrome. It is supplied as a single-dose vial as a white to off-white freeze-dried powder for reconstitution containing 40 mg of pantoprazole in packages of 10 and 25 vials.

For more information about PROTONOX I.V., log in to
*Call for eligibility through your GPO affiliation.


HIZENTRA (immune globulin subcutaneous [human] 20% liquid) PRE-FILLED SYRINGES for primary immunodeficiency patients are ready to use, eliminating the need to transfer the drug from the vial to a syringe. The syringes come in 5 mL and 10 mL (fully assembled) and 20 mL (requiring the plunger rod to be screwed onto the syringe stopper prior to use).

For more information about HIZENTRA PRE-FILLED SYRINGES, log in to

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Jan. 1, 2021, through March 30, 2021.

Calculate your current medicare IVIG/SCIG Rates
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
ASCENIV 90283 / J1599 ** **
BIVIGAM J1556 $140.98 $138.72
FLEBOGAMMA J1572 $73.72 $72.54
GAMMAGARD SD J1566 $133.94 $131.80
GAMMAPLEX J1557 $99.62 $98.02
OCTAGAM J1568 $83.26 $81.93
PANZYGA 90283 / J1599 ** **
PRIVIGEN J1459 $84.85 $83.49
CUTAQUIG 90284 / J3590 ** **
CUVITRU J1555 $139.44 $137.20
HIZENTRA J1559 $110.94 $109.16
HYQVIA J1575 $143.36 $141.06
XEMBIFY J1558 $146.87 $144.51
GAMMAGARD LIQUID J1569 $87.25 $85.85
GAMMAKED J1561 $87.35 $85.95
GAMUNEX-C J1561 $87.35 $85.95

* Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** ASP-based Medicare payment rate not yet available; payment rate assigned by your Medicare Administrative Contractor.

Log in to BioSupply for Immune Globulin Products


FFF customers may order the following complementary resources to help you with your practice:

Seasonal Flu Poster flu myths and facts brochure
immune globulin reference charts
•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to IG Living
IG Living Magazine cover
BioSupplyTrends Quarterly Magazine cover

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Subscribe to Biosupply Trends Quarterly Magazine
small Biosupply logo small MyFluVaccine logo Verified Inventory Program logo
Home | About | Advertise | Subscribe | Contact – © FFF Enterprises, Inc.